SLC25A42 and gastric cancer: In summary, our study revealed that upregulation of SLC25A42 promotes the growth while suppresses ferroptosis of GC cells by reprogramming lipid metabolism via upregulating the acetylation and thus expression of CPT2, suggesting that SLC25A42 represents a promising target for the treatment of GC.